Lack of Industry Incentive for Conducting Trials 开展试验缺乏行业激励
The patents for the main chemotherapeutic agents used in HAIC, including cisplatin, oxaliplatin, 5-FU, and epirubicin, have expired, thus weakening the motivation for the pharmaceutical industry to sponsor HAIC studies.
HAIC中使用的主要化疗药物，包括顺铂、奥沙利铂、5-FU和表柔比星的专利已经过期，从而削弱了制药行业赞助HAIC研究的动机。
All the aforementioned prospective trials were not sponsored by pharmaceutical companies but by academic or governmental institutions.
上述所有的前瞻性试验都不是由制药公司赞助的，而是由学术或政府机构赞助的。
Such sponsorship may limit the scale of these trials and the incentives for further investigations.
这种赞助可能会限制这些试验的规模和进行进一步调查的动机。
Several ongoing studies exploring the efficacy of HAIC in combination with novel anticancer agents, such as lenvatinib (Clinicaltrial.
一些正在进行的研究探索了HAIC与新型抗癌药物联合使用的疗效，如来伐替尼(临床试验。
gov: NCT04135690), apatinib (NCT03775395), camrelizumab (NCT04479527), and toripalimab (NCT04191889), have also been initiated by the investigators themselves.
gov：NCT04135690)、阿帕替尼(NCT03775395)、卡姆雷珠单抗(NCT04479527)和托帕利单抗(NCT04191889)也已由研究人员自己发起。
|